Cost-effectiveness of continuous glucose monitoring with remote patient monitoring in pediatric patients with newly diagnosed type 1 diabetes in the United States

Read full text Summarise with VIRAT
Authors: Paul Dupenloup, Yupeng Chen, Priya Prahalad, Ramesh Johari, Ananta Addala, Dessi P. Zaharieva, Ming Yeh Lee, David M. Maahs, David Scheinker, Margaret L. Brandeau
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: The use of continuous glucose monitoring (CGM) with remote patient monitoring (RPM) continues to grow. We evaluated the cost-effectiveness of CGM with RPM compared to self-monitoring of blood glucose (SMBG) and CGM alone. Research design and methods: We simulated type 1 diabetes progression with a Markov model in 5-year-old patients over a 20-year, 50-year, and age 100 horizon. We tracked diabetic ketoacidosis (DKA), severe hypoglycemia (SH), and seven chronic complications: retinopathy, neuropathy, nephropathy, cardiovascular disease, end-stage renal disease, lower-extremity amputation, and blindness. We compared three interventions: SMBG, CGM, and CGM with RPM. Efficacy estimates were derived from meta-analyses of pediatric CGM studies and the results of the Teamwork, Targets, Technology, and Tight Glycemia Study (4T Study 1). We evaluated quality-adjusted life years (QALYs) and healthcare costs (2022 U.S. dollars) discounted at 3% annually. We performed extensive sensitivity analyses. Results: Compared to SMBG, CGM increased QALYs by 0.09 and costs by $8,900 over 20 years; CGM with RPM increased QALYs by 0.37 and costs by $10,300 CGM with RPM yielded more QALYs at a lower incremental cost-effectiveness ratio compared to CGM ($27,400/QALY vs $103,700/QALY, respectively). Results were robust across sensitivity analyses and time horizons. CGM with RPM remained cost-effective when achieving at least 30% of 4T’s clinical efficacy. Conclusions: CGM with RPM delivers superior health outcomes compared to SMBG and CGM and is likely cost-effective for patients with newly diagnosed type 1 diabetes. Despite higher intervention costs, CGM with RPM can reduce complications costs and generate net healthcare savings.

Fields of Study & Subjects

Diabetes Management and Research Health Systems Economic Evaluations Quality of Life Diabetes Management and Education

Publication details

Publication date
25 March 2026
Language
EN